Evidence map›Paper›PMID 42717077›Full record

ArticleEuropean journal of clinical pharmacology2026

Association between body mass index and serum concentrations of olanzapine and selective serotonin reuptake inhibitors in patients with eating disorders.

Vilde Hersleth, Olav Spigset, Siri Weider, Elise Koch, Ole A Andreassen, Stian Lydersen, Katrine Kveli Fjukstad

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Vilde HerslethDepartment of Mental Health, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
Olav SpigsetDepartment of Clinical Pharmacology, St. Olav University Hospital, Trondheim, Norway.ORCID http://orcid.org/0000-0001-7902-9014
Siri WeiderDepartment of Psychology, Faculty of Social and Educational Sciences, Norwegian University of Science and Technology, Trondheim, Norway.ORCID http://orcid.org/0000-0002-9172-309X
Elise KochCentre for Precision Psychiatry, Division of Mental Health and Addiction, Institute of Clinical Medicine, Oslo University Hospital, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0003-3727-4470
Ole A AndreassenCentre for Precision Psychiatry, Division of Mental Health and Addiction, Institute of Clinical Medicine, Oslo University Hospital, University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0002-4461-3568
Stian LydersenDepartment of Mental Health, Faculty of Medicine and Health Sciences, Regional Centre for Child and Youth Mental Health and Child Welfare, Norwegian University of Science and Technology, Trondheim, Norway.
Katrine Kveli FjukstadDepartment of Mental Health, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway. katrine.k.fjukstad@ntnu.no.ORCID http://orcid.org/0000-0002-0909-1266

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSelective serotonin reuptake inhibitors (SSRIs) and olanzapine are frequently prescribed for patients with anorexia nervosa and bulimia nervosa. The effect of severely low body mass index (BMI) on the pharmacokinetics of these drugs has received little attention. The aim was to investigate the association between BMI and dose-adjusted serum concentrations (concentration/dose ratios; CDRs) of SSRIs and olanzapine in patients with eating disorders.

methodWe conducted a retrospective analysis of patients from a regional center for eating disorders. BMI, daily doses of olanzapine and SSRIs, and their serum concentrations were obtained from medical records. Linear regression analyses were conducted with CDR for each drug as dependent variable and BMI as independent variable. A group of patients with schizophrenia or bipolar disorder was included for comparison of patients with BMI in the normal range.

resultsSixty-five patients with eating disorders and 545 patients from the comparison group were included. Among the patients with eating disorders, there were no significant associations between BMI and CDRs for any of the drugs. CDR for olanzapine was significantly higher in the eating disorder group than in the comparison group, but most of this difference could be attributed to the higher proportion of smokers in the comparison group.

conclusionThis study suggests that patients with eating disorders do not have clinically important changes in CDRs of SSRIs and olanzapine related to their low BMI. Although reassuring, the number of included patients treated with each drug is low.

Indexed as

Antipsychotic AgentsBenzodiazepinesBody Mass IndexFeeding and Eating DisordersOlanzapineSelective Serotonin Reuptake InhibitorsAdolescentAdultFemaleHumansMaleRetrospective StudiesSchizophreniaYoung AdultAntipsychotic AgentsBenzodiazepinesOlanzapineSelective Serotonin Reuptake InhibitorsAnorexia nervosaBody mass indexBulimia nervosaDrug concentrationsOlanzapineSelective serotonin reuptake inhibitorsTherapeutic drug monitoring

Identifiers

PMID42717077
PMCPMC13558376

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.